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E-mail address: philippe.carruzzo@unil.ch (P. Carruzzoa b s t r a c tBackground: While the association between smoking and arterial cardiovascular events has been well
established, the association between smoking and venous thromboembolism (VTE) remains controversial.
Objectives: To assess the association between smoking and the risk of recurrent VTE and bleeding in patients who
have experienced acute VTE.
Patients/methods: This study is part of a prospective Swiss multicenter cohort that included patients aged
≥65 years with acute VTE. Three groups were defined according to smoking status: never, former and current
smokers. The primary outcome was the time to a first symptomatic, objectively confirmed VTE recurrence.
Secondary outcomes were the time to a first major and clinically relevant non-major bleeding. Associations
between smoking status and outcomes were analysed using proportional hazard models for the subdistribution
of a competing risk of death.
Results: Among 988 analysed patients, 509 (52%) had never smoked, 403 (41%) were former smokers, and 76
(8%) current smokers. After a median follow-up of 29.6 months, we observed a VTE recurrence rate of 4.9 (95%
confidence interval [CI] 3.7–6.4) per 100 patient-years for never smokers, 6.6 (95% CI 5.1–8.6) for former
smokers, and 5.2 (95% CI 2.6–10.5) for current smokers. Compared to never smokers, we found no association
between current smoking and VTE recurrence (adjusted sub-hazard ratio [SHR] 1.05, 95% CI 0.49–2.28), major
bleeding (adjusted SHR 0.59, 95% CI 0.25–1.39), and clinically relevant non-major bleeding (adjusted SHR 1.21,
95% CI 0.73–2.02).
Conclusions: In this multicentre prospective cohort study, we found no association between smoking status and
VTE recurrence or bleeding in elderly patients with VTE.Keywords:
Venous thromboembolism
Recurrence
Hemorrhage
Smoking
Aged1. Introduction
Venous thromboembolism (VTE), defined as deep vein thrombosis
(DVT) and/or pulmonary embolism (PE), is a common disease [1]. The
incidence of VTE increases with age, rising from b1 case per 1000
person-years in persons aged b50 years to more than 6 cases per 1000
person-years in persons aged N80 years [2–6]. Overall, 60% of VTE
events occur in persons aged ≥65 years [1,2,7].
Several factors induced by smoking could promote the formation of
a clot and the subsequent VTE. Thesemechanismswere often studied in
researches on atherosclerosis, and smoking shares common biologicalsitaire, Rue duBugnon 44, 1005
).consequences on the venous system. Smoking causes endothelial
damage that can lead to a reduced capacity for dilatation (by a
decreased activity of nitrous oxide) and increased vessel contraction
(by stimulation of the release of catecholamines) [8–11]. This endothe-
lial damage can lead to pro-thrombotic and pro-inflammatory states
with an increased production of cytokines including IL-6, IL1B and
TNFα [8–11]. Those cytokines playmajor regulatory roles in the hepatic
synthesis of acute phase proteins, including fibrinogen. As IL-6 appears
to be the principal procoagulant cytokine in humans, it could be an
important link to VTE [11,12]. Moreover, there is a clear dose–effect
relationship between number of cigarettes smoked per day and raised
plasma fibrinogen concentration and conversely a reduction of it with
smoking cessation [13].
The association between smoking and VTE remains controversial.
While a meta-analysis reported no statistically significant relationship
between smoking and first VTE (odds ratio [OR] 1.18, 95% confidence
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cigarette smoking was associated with a slightly increased risk for first
VTE (pooled relative risk 1.23, 95% CI 1.14–1.33) in current smokers
compared with never smokers [15].
Smoking interacts directly with the metabolism of vitamin K
antagonists by increasing the required dosage to achieve and maintain
a therapeutic international normalized ratio [16], potentially increasing
the risk of VTE recurrence. Pathophysiologically, smoking may increase
the clearance of warfarin and in this way reduce its anticoagulant
effect. Therefore, smoking cessation or a decrease in smoking may
lead to overanticoagulation and an increased risk of bleeding.
Evidence suggests that elderly patients who have experienced an
acute VTE may have a higher risk of VTE recurrence, bleeding, and
death than younger patients [2,7]. Given that the elderly are a rapidly
growing population segment in Western societies and almost half of
the elderly population is or has been exposed to smoking [17], it is of
interest to examine the possible association between smoking and
VTE recurrence and bleeding in this population. In a prospective multi-
center cohort study, we aimed to assess the association between
smoking status and the risk of recurrent VTE and bleeding in elderly
patients with acute VTE.
2. Methods
2.1. Cohort sample
The study was conducted between September 2, 2009 and
December 6 2013 as part of Swiss Cohort of Elderly Patients with
Venous Thromboembolism (SWITCO65+), a prospective, multicenter
cohort study that assessed long-term medical outcomes in elderly
patients with acute VTE from all five university and four high-volume
non-university hospitals in Switzerland. Consecutive patients aged
≥65 years with acute, objectively confirmed symptomatic VTE were
prospectively identified in the inpatient and outpatient services of all
participating study sites. Exclusion criteria were catheter-related
thrombosis, insufficient German or French-speaking ability, no follow-
up possible (i.e., terminal illness), an inability to provide informed
consent (i.e., severe dementia), or previous enrollment in the cohort.
The detailed methodology of the SWITCO65+ cohort has been de-
scribed elsewhere [2]. The study has been approved by the Institutional
Review Board at each participating center. For the present study, we
excluded patients with missing information about their smoking
status.
2.2. Baseline data collection
For all enrolled patients, trained studynurses prospectively collected
information about baseline demographics (age, gender, insurance
status, living status, and educational level), comorbid conditions (active
cancer, hepatic, cardiac, lung, renal, and cerebrovascular disease, and
history of major bleeding), traditional cardiovascular risk factors
(arterial hypertension, diabetes mellitus, hypercholesterolemia,
body mass index, physical activity level), risk factors for VTE (active
cancer, recent immobilization, major surgery, estrogen therapy), type
and localization of the index VTE, VTE-related treatments (oral and
parenteral anticoagulants), and concomitant antiplatelet/non-steroidal
anti-inflammatory drug therapy using standardized data collection
forms.
Smoking habits, including self-reported smoking status, the average
number of cigarettes smoked per day and years of smoking were
assessed. We defined three possible smoking statuses: current smokers
(i.e. patients reporting smoking ≥1 cigarette per day at the time of
the interview), former smokers (defined as smokers who had quit for
N6 months) and never smokers. Current and former smokers were
classified into three subgroups according to the number of pack-
years smoked (defined as the number of packs of cigarettes smokedper day multiplied by the duration of smoking in years): ≤20, 21–40,
and N40 pack-years.
2.3. Study outcomes
The primary outcome was the time to the recurrence of symptom-
atic, objectively confirmed VTE during follow-up, defined as new
or recurrent PE or DVT based on previously published criteria [18,19].
We defined recurrent symptomatic VTE as acute chest pain, new or
worsening dyspnea or cough, acute hemoptysis, or syncope coupled
with an objective diagnosis of pulmonary embolism based on spiral
computed tomography, pulmonary angiography, or autopsy, or a new
unilateral leg pain or swelling coupled with an objective diagnosis
of deep vein thrombosis based on ultrasonography or contrast
venography.
The secondary outcome was the time to a first bleeding event. We
defined major bleeding as fatal bleeding, symptomatic bleeding in a
critical organ (intracranial, intra-spinal, intraocular, retroperitoneal,
intra-articular, pericardial, or intramuscular with compartment syn-
drome), bleeding with a reduction of hemoglobin ≥20 g/l, or bleeding
leading to the transfusion of 2 units of packed red blood cells or more
[2,20]. Non-major bleedingwas defined as bleeding leading to amedical
consultation or a visit to an emergency center, without fulfilling the
criteria for a major bleeding [2].
Follow-up included one telephone interview and two surveillance,
face-to-face evaluations during the first year of study participation
and then semi-annual contacts, alternating between face-to-face
evaluations (clinic visits or home visits in house-bound patients) and
telephone calls as well as periodic reviews of the patient's hospital
chart. During each visit/contact, study nurses interviewed patients
to obtain information about the date and type of clinical events
(recurrent VTE, bleeding, and death). If a clinical event had occurred,
this information was complemented by reviewing medical charts and
interviewing patients' primary care physicians and family members.
We assessed outcomes using patient or proxy interviews, interview
of the patient's primary care physician, and/or hospital chart review.
A committee of three blinded clinical experts adjudicated all outcomes
and classified the cause of all deaths as definitely due to PE, possibly
due to PE, due to major bleeding, or due to another cause. Final
classification was made on the basis of the full consensus of this
committee.
2.4. Statistical analysis
We compared baseline and outcome characteristics of never,
current, and former smokers using chi-squared test for categorical
variables and non-parametric Kruskal–Wallis test for continuous
variables. Smoking characteristics of current and former smokers
were compared using chi-squared and Wilcoxon rank-sum test
as appropriate. We calculated the incidence rate of a first VTE
recurrence in each group and compared incidences among
groups using the incidence rate ratio. We estimated the cumulative
incidence of a first VTE recurrence by the Kaplan–Meier method and
compared survivor functions across groups of patients with different
smoking status and the quantity of pack-years smoked by the logrank
test.
We compared the percentage of time spent within one of
three specified INR ranges (b2.0, 2.0–3.0, N3.0) across different
smoking levels by analysis of variance (ANOVA), excluding the
first seven treatment days and patients with no or only one INR
measurement.
Associations between smoking status and the time to the first VTE
recurrence were assessed by competing risk regression accounting for
death as a competing event, according to the method of Fine and Gray
(1999) [21]. The method yields sub-hazard ratios (SHR) with corre-
sponding 95% confidence intervals (CIs). Adjustments were done for
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including prior VTE, active cancer, overt PE, and provoked VTE (defined
as the presence of immobilization, major surgery, or current estrogen
therapy during the last 3 months). For bleeding, adjustments were
done for age and gender and for variables known to be associated
with a higher bleeding risk, including chronic renal disease or a creati-
nine clearance b30 ml/min., history of major bleeding, anemia, and
concomitant antiplatelet treatment [22–25]. We adjusted all analyses
for periods of anticoagulation treatment as a time-varying covariate.
All analyses were done using Stata 13 (Stata Corporation, College
Station, Texas).
3. Results
Of the 1003 patients enrolled in the cohort, 15 were excluded
who did not allow use of their data (n = 8), withdrew early (n = 4),
or missed information about smoking status (n = 3). Therefore,
the final study sample comprised 988 patients of whom 509 (52%)
had never smoked, 403 (41%)were former smokers and 76 (8%) currentTable 1
Baseline characteristics of the patients, by smoking status.
Current smokers
n = 76
Socio-demographic
Patient age, median (IQR) 74.0 (69.0; 79.0)
Gender (female), n (%) 19 (25.0%)
High school graduate or more, n (%) 36 (47%)
Living status, n (%)
Living at home with spouse, partner, or family member 50 (66%)
Living at home alone 23 (30%)
Living in nursing home 3 (4%)
Smoking characteristics
Average number of cigarettes per day, median (IQR) 15.0 (7.0; 20.0)
Years of smoking, median (IQR) 48.0 (30.0; 54.0)
Cigarettes in pack-years, median (IQR) 30.0 (15.0; 55.0)
Comorbidities/history of
Chronic or acute lung disease, n (%) 21 (28%)
Coronary heart disease, n (%) 16 (21%)
Arterial hypertension, n (%) 48 (63%)
Hypercholesterolemia, n (%) 28 (37%)
Diabetes mellitus, n (%) 14 (18%)
BMI, median (IQR) 26.0 (23.8; 29.8)
Low physical activity, n (%) 26 (34%)
Index VTE characteristics
Type of thrombosis, n (%)
distal DVT only 6 (7.9%)
proximal DVT 23 (30.3%)
pulmonary embolism 47 (61.8%)
Prior VTE, n (%) 18 (23.7%)
Provoked index VTEa, n (%) 24 (31.6%)
Immobilization during the last 3 months, n (%) 16 (21.1%)
Major surgery during the last 3 months, n (%) 11 (14.5%)
Current estrogen therapy during the last 3 months, n (%) 2 (2.6%)
Active cancer requiring therapy, n (%) 15 (19.7%)
Bleeding risk factors
Anemia, n (%) 25 (33%)
History of major bleeding, n (%) 10 (13%)
Chronic renal disease or CrCl b 30, n (%) 14 (18%)
Concomitant antiplatelet therapy, n (%) 29 (38%)
Type of initial parenteral AC, n (%)
LMWH 36 (47%)
UFH 26 (34%)
Fondaparinux 13 (17%)
Danaparoid 0 (0%)
None 1 (1%)
Vitamin K antagonist, n (%) 61 (80%)
N number, IQR interquartile range, n.a. non-applicable, VTE venous thromboembolism, DVT
anticoagulation.
Missing ≤ 0.5% for every variable except for anemia (6.4%).
a Defined as the presence of at least one out of three risk factors: immobilization, major sursmokers. The median follow-up duration was 29.6 months (IQR 18.8–
36.2).
Patient baseline characteristics are described in Table 1. Former
and current smokers reported a median of 16 and 30 pack-years,
respectively. Never smokers were more likely to be women and older
than current and former smokers. Not surprisingly, current and former
smokers were more likely to have lung disease and coronary heart
disease and to receive concomitant antiplatelet therapy than never
smokers. Finally, never smokers were more likely to receive vitamin K
antagonists.
Overall, 204patients (20%) died during follow-up and 120 (12%) had
recurrent VTE (Table 2). VTE recurrence did not vary by smoking status.
Furthermore, 131 patients (13%) had major and 199 (20%) non-major
bleeding events during the follow-up. Again, bleeding did not differ by
smoking status.
Table 3 shows the incidence rate and incidence rate ratio (IRR) of
VTE recurrence and major and non-major bleeding events for the
three categories of smokers. Generally, compared with never smokers,
current smokers tended to have a somewhat higher incidence rate ofFormer smokers
n = 403
Never smokers
n = 509
P-value
74.0 (69.0; 80.0) 76.0 (70.0; 82.0) 0.002
123 (31%) 319 (63%) b0.001
189 (47%) 219 (43%) 0.474
0.006
281 (69%) 296 (58%)
113 (28%) 200 (39%)
9 (2%) 12 (2%)
20.0 (7.0; 25.0) n.a.
20.5 (10.0; 38.3) n.a.
16.0 (5.0; 40.0) n.a.
80 (20%) 53 (10%) b0.001
91 (23%) 65 (13%) b0.001
254 (63%) 334 (66%) 0.701
129 (32%) 145 (29%) 0.241
74 (18%) 67 (13%) 0.080
26.7 (24.1; 29.8) 26.8 (24.1; 30.0) 0.797
154 (38%) 187 (37%) 0.783
0.531
35 (8.7%) 39 (7.7%)
87 (21.6%) 113 (22.2%)
281 (69.7%) 357 (70.1%)
128 (31.8%) 136 (26.7%) 0.153
128 (31.8%) 143 (28.1%) 0.458
98 (24.3%) 103 (20.2%) 0.329
65 (16.1%) 73 (14.3%) 0.747
12 (3.0%) 18 (3.5%) 0.849
83 (20.6%) 79 (15.5%) 0.127
177 (44%) 185 (36%) 0.093
41 (10%) 50 (10%) 0.672
92 (23%) 96 (19%) 0.303
143 (36%) 148 (29%) 0.065
0.772
193 (48%) 234 (46%)
139 (35%) 167 (33%)
58 (14%) 87 (17%)
1 (0.2%) 0 (0%)
12 (3%) 21 (4%)
342 (85%) 455 (89%) 0.028
deep vein thrombosis, TIA transient ischaemic accident, CrCl creatinine clearance, AC
gery, or current estrogen therapy during the last 3 months.
Table 2
Outcome data.
Current smokers
n = 76
Former smokers
n = 403
Never smokers
n = 509
P-value
Death during FU, n (%) 17 (22%) 89 (22%) 98 (19%) 0.536
VTE recurrence
VTE recurrence during FU, n (%) 8 (11%) 58 (15.1%) 54 (11%) 0.200
Incidence rate per 100 patient-years (95%-CI) 5.2 (2.6–10.5) 6.6 (5.1–8.6) 4.9 (3.7–6.4)
Incidence rate ratio (95%-CI) 1.1 (0.4–2.8) 1.4 (0.9–2.0) 1 (ref.)
Type of VTE recurrence, n (%) 0.729
Distal DVT only 1 (13%) 3 (5%) 5 (9%)
Proximal DVT only 3 (38%) 16 (28%) 12 (22%)
Pulmonary embolism 4 (50%) 39 (67%) 37 (69%)
Under anticoagulant therapy at time of VTE recurrencea, n (%) 3 (38%) 17 (29%) 12 (22%) 0.540
UFH 0 (.%) 2 (15%) 1 (11%) 0.774
LMWH 0 (.%) 1 (8%) 3 (33.3%) 0.149
Fondaparinux 0 (.%) 1 (8%) 0 (0.0%) 0.402
VKA 3 (100.0%) 14 (93%) 10 (91%) 0.858
Days between index VTE and recurrence, median (IQR) 230 (105; 257) 505 (209; 799) 396 (191; 678) 0.320
Bleeding
Major bleeding
Major bleeding during FU, n (%) 6 (8%) 59 (15%) 66 (13%) 0.271
Incidence rate per 100 patient-years (95%-CI) 3.9 (1.8–8.8) 6.9 (5.3–8.9) 6.0 (4.7–7.6)
Incidence rate ratio (95%-CI) 0.7 (0.2–1.5) 1.2 (0.8–1.7) 1 (ref.)
Non-major bleeding
Non-major bleeding during FU, n (%) 17 (22%) 85 (21%) 97 (19%) 0.659
Incidence rate per 100 patient-years (95%-CI) 11.4 (7.1–18.3) 10.5 (8.5–12.9) 9.4 (7.7–11.4)
Incidence rate ratio (95%-CI) 1.2 (0.7–2.0) 1.1 (0.8–1.5) 1 (ref.)
n number, FU follow-up, VTE venous thromboembolism, DVT deep vein thrombosis, UFH unfractionated heparin, LMWH low molecular weight heparin, VKA vitamin K antagonist, IQR
interquartile range.
a Multiple options possible.
Table 3
Association between smoking and risk of VTE recurrence and bleeding events.
Current smokers n = 76 Former smokers n = 403 Never smokers n = 509
VTE recurrence
Crude SHR (95%-CI) 1.04 (0.49 to 2.2) 1.35 (0.93 to 1.96) 1 (ref.)
Adjusted⁎ SHR (95%-CI) 1.05 (0.49 to 2.28) 1.33 (0.90 to 1.98) 1 (ref.)
Bleeding
Major bleeding
Crude SHR (95%-CI) 0.61 (0.26 to 1.41) 1.14 (0.80 to 1.61) 1 (ref.)
Adjusted SHR (95%-CI) 0.59 (0.25 to 1.39) 1.09 (0.76 to 1.55) 1 (ref.)
Non-major bleeding
Crude SHR (95%-CI) 1.22 (0.73 to 2.04) 1.10 (0.82 to 1.47) 1 (ref.)
Adjusted SHR (95%-CI) 1.21 (0.73 to 2.02) 1.09 (0.81 to 1.47) 1 (ref.)
⁎ Adjusted for age, gender, for VTE: prior VTE, provoked VTE, active cancer, overt PE, for bleeding: chronic renal disease or CrCl b 30 ml/min, history of major bleeding, anemia,
and concomitant antiplatelet treatment.
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(IRR 1.2 95% CI 0.7–2.0) but a lower incidence of major bleeding events
(IRR 0.7 95% CI 0.2–1.5).
After adjustment, current smokers did not have a statistically signifi-
cantly increased risk of VTE recurrence compared with never smokers
(adjusted SHR1.05 95%CI 0.49–2.28). Similarly, therewas no statistically
significant association between active smoking and major (adjusted
SHR 0.59 95% CI 0.25–1.39) and non-major bleeding events (adjusted
SHR 1.21 95% CI 0.73–2.02). We did not observe a statistically significant
association between former smoking status and VTE recurrence
or bleeding events. Moreover, we found no dose–response relationship
between the number of pack-years and VTE recurrence in current
and former smokers (data not shown). In patients who received
treatment with vitamin K antagonists, the percentage of time spent
in the therapeutic range did not vary by smoking status (data not
shown).
4. Discussion
In this prospective cohort of elderly patients with VTE, the incidence
of recurrent VTE and bleeding did not vary by smoking status.We foundno dose–response relationship between the number of pack-years
smoked and VTE recurrence. After adjustment, smoking status was
neither associated with recurrent VTE nor with bleeding.
In the present study, the prevalence of active smoking (8%) was
similar to that observed in the general Swiss population aged 65 years
or older [26] but former smokers were over represented in this cohort
(41% vs 33.3% for 65–74 years old and 26.7% for ≥75 years old in the
general Swiss population).
While the relationship between smoking and the first VTE has been
well studied, very few studies have examined the relationship between
smoking status and recurrent VTE. A cross-sectional study on the impact
of cardiovascular risk factor on the risk of recurrent VTE reported no
statistically significant association between cigarette smoking and
recurrence of VTE (hazard ratio [HR] 1.20, 95% CI 0.88–1.52) [27]. In
this study of younger patients (mean age 43.5 years), the authors did
not differentiate current smokers from former smokers and compared
ever smokers (current and former smokers) to never smokers. The
reason why smoking seems to be associated with a first VTE but not
with recurrent VTE remains unclear. However, after a first VTE event,
smokers might reduce their cigarette consumption or make quit
attempts, thus decreasing the risk of recurrent VTE. This might partly
Published in final edited form as: Thromb Res. 2016 Feb;138:74-79. doi: 10.1016/j.thromres.2015.11.034explain why smoking was not associated with an increased risk of VTE
recurrence in the present study.
Regarding the possible dose–response relationship between
smoking and VTE recurrence, we found no association between number
of pack-years and VTE recurrence. A large population-based case–
control study showed a clear dose-dependent, reversible association of
smoking and the risk of a first VTE [28]. The limited number of smokers
in our study (n = 76) might explain the absence of significant dose–
response relationship.
In this cohort, smoking was not associated with an increased risk
of major and clinically relevant non-major bleeding. Evidence suggests
that smokers may need higher doses of warfarin per week than
nonsmokers [16]. Smoking not only increases the dosage of required
oral anticoagulant, but the variation of smoking amount or frequency
may have an influence on the stability of anticoagulation making it
difficult to maintain the anticoagulation in the therapeutic range.
However, to our knowledge, there are no studies exploring the effect
of smoking on the quality of oral anticoagulation. In our study, we
found no difference in the percentage of time in the therapeutic range
between smokers, former smokers, and never smokers. This may be
due again to the limited sample of smokers. This study contains no
information on quitting smoking, variation of consumption of cigarettes
during the week or increased or decreased mean consumption of
cigarettes.
The main strength of the study is that it prospectively followed
patients over 3 years. It is the first prospective study examining
the association between smoking status and outcomes in patients with
VTE.
Our study has potential limitations. First, the study sample may not
reflect the full prognostic spectrum of patients with VTE because
analysed patients were younger andmore likely to bemen than exclud-
ed patients. Thus we cannot rule out the possibility that the association
between smoking status and bleeding and VTE recurrence would have
been different inmore severely ill patients. Second, an important limita-
tion of this study is the small number of current smokers and the conse-
quent lack of statistical power of our analysis. Moreover, the smoking
status and number of cigarettes smoked a day were self-reported by
patients and might be underestimated. Finally, smoking status was
only assessed at baseline and was not updated over follow-up (no
information on initiation, cessation or relapse of smoking). However,
we can assume that initiation of smoking in a population age N 65 years
old is very unusual. Finally, our results are valid only for a Caucasian
European population, given the relatively high socio-economical status
of the population included and are not generalizable to other
populations.
In conclusion, we found no differences in anticoagulation quality
in smokers, former smokers, and never smokers in this prospective
cohort of elderly patients with VTE. Moreover, smoking status was
not significantly associated with VTE recurrence or bleeding. This
study investigated for the first time the impact of smoking in this
population.Addendum
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